Scarica l'app Stockscreener
21.99
1.30%
-0.29
Dopo l'orario di chiusura:
21.99
Precedente Chiudi:
$22.28
Aprire:
$22.31
Volume 24 ore:
1.17M
Relative Volume:
0.68
Capitalizzazione di mercato:
$2.72B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-7.1165
EPS:
-3.09
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
-12.53%
1M Prestazione:
+8.92%
6M Prestazione:
+158.40%
1 anno Prestazione:
+44.96%
Intervallo 1D:
$21.81
$22.70
Intervallo di 1 settimana:
$20.35
$24.00
Portata 52W:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.99 | 2.76B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences amends loan agreement, extends maturity and updates terms - Investing.com
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms - TipRanks
Cancer-focused Arcus Biosciences to present at major health conference - Stock Titan
February 2026 Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 (NYSE:RCUS) - Seeking Alpha
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? - inkl
RCUS Stock Down on Decision to Discontinue GILD Partnered Study - Finviz
Arcus Biosciences stock price target raised to $32 at H.C. Wainwright - Investing.com Canada
Domvanalimab failure bad news for Arcus and TIGIT class - The Pharma Letter
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Assessing Arcus Biosciences’ Valuation After Halting Key GI Trials and Pivoting to Casdatifan-Focused Strategy - simplywall.st
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update - ts2.tech
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next - Yahoo Finance
Arcus Biosciences (NYSE:RCUS) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Arcus Biosciences (NYSE:RCUS) Shares Gap DownHere's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
Arcus Biosciences Target of Unusually Large Options Trading (NYSE:RCUS) - MarketBeat
Gilead, Arcus scrap late-stage trial of cancer drug combo - WTVB
Why Arcus Biosciences just reversed its 287% eight-month winning streak - MSN
HC Wainwright & Co. Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination - Citeline News & Insights
Arcus shifts effort, bears down on would-be ‘anchor’ in RCC - BioWorld MedTech
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney DrugArcus Biosciences (NYSE:RCUS) - Benzinga
H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses - Investing.com Canada
Truist Securities lowers Arcus Biosciences stock price target on trial failure - Investing.com Canada
Why Did Arcus Biosciences Stock Slump 10% Today? - Asianet Newsable
RCUS: HC Wainwright & Co. Raises Price Target for Arcus Bioscien - GuruFocus
Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive
Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating - marketscreener.com
Arcus Biosciences (RCUS) Shares Decline Over 11% in Recent Tradi - GuruFocus
Arcus scraps late-stage cancer trial after weak survival data - Reuters
Arcus Biosciences (RCUS) Drops After Halting Phase 3 Cancer Tria - GuruFocus
Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study - TipRanks
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment - marketscreener.com
Arcus Biosciences stock falls after discontinuing phase 3 cancer study By Investing.com - Investing.com Australia
Arcus Biosciences Discontinues Phase 3 STAR-221 Study - TradingView — Track All Markets
Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio - TradingView — Track All Markets
Arcus Biosciences stock falls after discontinuing phase 3 cancer study - Investing.com
Arcus Biosciences (NYSE: RCUS) ends STAR-221, backs casdatifan and I&I pipeline into 2028 - Stock Titan
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $431,000 Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Decliners Report: Why Arcus Biosciences Inc stock attracts global investors2025 Volatility Report & Weekly Watchlist for Consistent Profits - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RCUS) Movement - news.stocktradersdaily.com
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (NYSE: RCUS) sets $25.80 inducement grant under 2020 plan - Stock Titan
Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Arcus Biosciences Stock Built to Withstand a Pullback? - Trefis
Fisher Asset Management LLC Decreases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.31%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):